Genomic alterations drive more than 60% of adenocarcinoma cases of NSCLC.1 Approximately 25% of these cases will have an oncogenic driver (EGFR, ALK, ROS1, BRAF, or NTRK) that can be […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events